Filing Flows › PTC Therapeutics (PTCT) › R&D spending
PTC Therapeutics (PTCT) R&D spending by quarter
PTC Therapeutics' R&D spending was $105M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 7 quarters it ranged from $99.2M (Q2 2026) to $133M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $105M | +6% | +5% |
| Q2 2026 | $99.2M | -2% | -12% |
| Q1 2026 | $101M | -24% | -7% |
| Q4 2025 | $133M | +33% | — |
| Q3 2025 | $100M | -11% | — |
| Q2 2025 | $113M | +4% | — |
| Q1 2025 | $109M | — | — |
Q3 2026 at a glance
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is PTC Therapeutics' R&D spending?
PTC Therapeutics' R&D spending was $105M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has PTC Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $99.2M (Q2 2026) to $133M (Q4 2025).